The article discusses struggle faced by development of drug resistance. It states that human immunodeficiency virus (HIV) patients who receive weekly anti tuberculosis therapy are at higher risk of acquired rifampicin resistance and showed that cotrimoxazole was active against tuberculosis and increased efficacy of rifampicin treatment. It mentions that therapeutic drug monitoring (TDM) joined with drug awareness testing may help to develop treatment in patients.